Larimar Therapeutics Inc. (LRMR)
LRMR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2019-12-31, https://www.sec.gov/Archives/edgar/data/1374690/000156459020008984/0001564590-20-008984-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2019-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | LRMR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001374690 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2019
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$23.1M |
| Operating income | -$23.2M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $1.0M |
| Total assets | $5.2M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These conditions raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-08-04 |
| Cash and burn | $92.7M cash; operating cash flow -$33.6M a quarter. | Report 2026-06-30 |
| Shares outstanding | 103,882,937 (2026-08-02); 85,590,392 a year earlier; 43,277,500 three years earlier. | Cover page 2026-08-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-02-26 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $25.7M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$32.8M | -$44.0M | $92.7M | No debt tags | Needs four quarters | 10-Q 2026-08-04 |
| Q1 2026 2026-03-31 | Not filed | -$29.6M | -$44.6M | $177.9M | No debt tags | Needs four quarters | 10-Q 2026-08-04 |
| Q4 2025 2025-12-31 | Not filed | -$62.5M | Not filed | $85.4M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
| Q3 2025 2025-09-30 | Not filed | -$47.7M | Not filed | $90.1M | No debt tags | Needs four quarters | 10-Q 2025-11-05 |
| Q2 2025 2025-06-30 | Not filed | -$26.2M | -$19.4M | $20.6M | No debt tags | Needs four quarters | 10-Q 2026-08-04 |
| Q1 2025 2025-03-31 | Not filed | -$29.3M | -$26.5M | $21.1M | No debt tags | Needs four quarters | 10-Q 2026-08-04 |
| Q4 2024 2024-12-31 | Not filed | -$28.8M | -$21.8M | $33.2M | No debt tags | Needs four quarters | 10-K 2026-03-19 |
| Q3 2024 2024-09-30 | Not filed | -$15.5M | -$24.5M | $35.1M | No debt tags | Needs four quarters | 10-Q 2025-11-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-02-26 |
| Latest annual report | 10-K | 2026-03-19 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-04-20 |
Source: SEC EDGAR submissions feed, 709 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +26.4% |
| 1 month | +39.8% |
| 3 months | -29.3% |
| Year to date | -20.7% |
| 1 year | -8.2% |
| From 52-week high | -49.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ENTA | Enanta Pharmaceuticals Inc. | $10.67 | -2.91% | $310.8M |
| BNTC | Benitec Biopharma Inc. | $8.54 | -5.53% | $308.5M |
| GALT | Galectin Therapeutics Inc. | $3.02 | -0.98% | $305.2M |
| ALT | Altimmune Inc. | $1.56 | -5.17% | $303.6M |
| EBS | Emergent BioSolutions Inc. | $5.81 | +0.35% | $298.7M |
| EVMN | Evommune Inc. | $7.10 | -6.95% | $293.6M |
| AVIR | Atea Pharmaceuticals Inc. | $4.12 | -4.19% | $330.9M |
| FULC | Fulcrum Therapeutics Inc. | $3.71 | -1.59% | $283.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier